Vermillion Shares Outstanding 2006-2019 | VRML

Vermillion shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Vermillion Annual Shares Outstanding
(Millions of Shares)
2018 70
2017 57
2016 52
2015 47
2014 36
2013 21
2012 15
2011 14
2010 10
2009 7
2008 6
2007
2006
2005
Vermillion Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 76
Q4 2018 70
Q3 2018 75
Q2 2018 69
Q1 2018 60
Q4 2017 57
Q3 2017 57
Q2 2017 56
Q1 2017 54
Q4 2016 52
Q3 2016 52
Q2 2016 52
Q1 2016 52
Q4 2015 47
Q3 2015 50
Q2 2015 43
Q1 2015 43
Q4 2014 36
Q3 2014 36
Q2 2014 36
Q1 2014 36
Q4 2013 21
Q3 2013 23
Q2 2013 20
Q1 2013 15
Q4 2012 15
Q3 2012 15
Q2 2012 15
Q1 2012 15
Q4 2011 14
Q3 2011 15
Q2 2011 15
Q1 2011 13
Q4 2010 11
Q3 2010 10
Q2 2010 10
Q1 2010 10
Q4 2009 7
Q3 2009 6
Q2 2009 6
Q1 2009 6
Q4 2008
Q3 2008
Q2 2008
Q1 2008
Q4 2007
Q3 2007
Q2 2007
Q1 2007
Q4 2006
Q3 2006
Q2 2006
Q1 2006
Q4 2005
Q3 2005
Q2 2005
Q1 2005
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $0.086B $0.003B
Vermillion, Inc. is engaged in the discovery, development and commercialization of novel diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company has diagnostic programs in oncology, hematology, cardiology and women's health. Its tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Vermillion also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others. Its lead product includes the OVA1 ovarian tumor triage test, which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. In addition to the OVA1 Test, Vermillion has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. Vermillion, Inc. is based in Fremont, California.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $115.527B 25.27
Intuitive Surgical (ISRG) United States $60.928B 56.14
Edwards Lifesciences (EW) United States $39.801B 39.77
IDEXX Laboratories (IDXX) United States $24.444B 64.13
Fresenius Medical Care AG KGaA (FMS) Germany $24.394B 16.03
Teleflex (TFX) United States $15.460B 33.50
Olympus (OCPNY) Japan $15.407B 115.28
SONOVA HOLDING (SONVY) Switzerland $14.561B 0.00
Sysmex ADR (SSMXY) Japan $14.417B 38.87
DexCom (DXCM) United States $13.759B 269.84
Hologic (HOLX) United States $12.689B 20.41
STERIS (STE) Ireland $12.575B 30.42
Varian Medical Systems (VAR) United States $12.300B 31.38
ABIOMED (ABMD) United States $11.800B 71.79
Masimo (MASI) United States $8.237B 50.47
Penumbra (PEN) United States $6.000B 254.01
SARTORIUS AG (SARTF) Germany $5.850B 53.60
Elekta AB (EKTAY) Sweden $5.153B 38.83
Integra LifeSciences Holdings (IART) United States $4.599B 21.61
Globus Medical (GMED) United States $4.096B 25.54
Tandem Diabetes Care (TNDM) United States $3.740B 0.00
LivaNova (LIVN) United Kingdom $3.605B 23.50
Wright Medical Group (WMGI) Netherlands $3.365B 667.00
Cantel Medical (CMD) United States $3.364B 34.13
Glaukos (GKOS) United States $2.750B 0.00
Integer Holdings (ITGR) United States $2.675B 19.71
Nihon Kohden (NHNKY) Japan $2.449B 24.64
AVANOS MEDICAL, INC (AVNS) United States $2.029B 32.12
Nevro (NVRO) United States $1.983B 0.00
Inogen (INGN) United States $1.373B 30.40
OPKO Health (OPK) United States $1.317B 0.00
Silk Road Medical (SILK) United States $1.239B 0.00
Veracyte (VCYT) United States $1.167B 0.00
CryoLife (CRY) United States $1.116B 110.70
Accelerate Diagnostics (AXDX) United States $1.055B 0.00
Tactile Systems Technology (TCMD) United States $1.032B 152.33
ORTHOFIX MEDICAL INC (OFIX) United States $0.983B 28.48
Mesa Laboratories (MLAB) United States $0.912B 42.88
Pacific Biosciences Of California (PACB) United States $0.910B 0.00
ViewRay (VRAY) United States $0.907B 0.00
Luminex (LMNX) United States $0.882B 115.35
Natus Medical (BABY) United States $0.880B 20.37
AngioDynamics (ANGO) United States $0.810B 26.55
AxoGen (AXGN) United States $0.767B 0.00
Fluidigm (FLDM) United States $0.759B 0.00
Quotient (QTNT) Switzerland $0.696B 0.00
Intersect ENT (XENT) United States $0.651B 0.00
Corindus Vascular Robotics (CVRS) United States $0.581B 0.00
OrthoPediatrics (KIDS) United States $0.541B 0.00
Si-Bone (SIBN) United States $0.483B 0.00
GenMark Diagnostics (GNMK) United States $0.361B 0.00
Oxford Immunotec Global (OXFD) United Kingdom $0.354B 18.99
RTI Surgical (RTIX) United States $0.312B 38.36
Accuray (ARAY) United States $0.309B 0.00
TransEnterix (TRXC) United States $0.304B 0.00
Semler Scientific (SMLR) United States $0.289B 57.37
SeaSpine Holdings (SPNE) United States $0.245B 0.00
Neuronetics (STIM) United States $0.235B 0.00
ConforMIS (CFMS) United States $0.231B 0.00
Alphatec Holdings (ATEC) United States $0.208B 0.00
IRadimed (IRMD) United States $0.203B 38.64
CRH Medical (CRHM) Canada $0.201B 69.75
Sientra (SIEN) United States $0.180B 0.00
Stereotaxis (STXS) United States $0.172B 0.00
Second Sight Medical Products (EYES) United States $0.100B 0.00
Ekso Bionics Holdings (EKSO) United States $0.093B 0.00
Sensus Healthcare (SRTS) United States $0.088B 0.00
EDAP TMS S.A (EDAP) France $0.078B 0.00
Covalon Technologies (CVALF) Canada $0.070B 0.00
T2 Biosystems (TTOO) United States $0.069B 0.00
Apollo Endosurgery (APEN) United States $0.066B 0.00
Spectral Diagnostics (EDTXF) Canada $0.066B 0.00
Helius Medical Technologies (HSDT) United States $0.053B 0.00